Latest Updates in Immunology, Immunotherapy, and Hypersensitivity Reactions Treatment

In the past three years, the field of immunology has seen significant advancements across various domains, including the understanding of immune disorders, cancer immunotherapy, and the impact of COVID-19 on immune responses. Here are some of the key updates and developments:

A) Key Updates in Immunology and Immunotherapy.

1- Advancements in Inborn Errors of Immunity

The **International Union of Immunological Societies (IUIS**) updated its classification of inborn errors of immunity in 2022, identifying 55 novel monogenic gene defects. This brings the total number of recognized inborn errors to 485. These findings enhance the understanding of the genetic basis of immune diseases, aiding in molecular diagnosis and improving patient management.

2- Cancer Immunotherapy Innovations

The landscape of cancer immunotherapy has evolved significantly:

I. **Immune Checkpoint Inhibitors (ICIs):** As of mid-2023, the FDA has approved 11 ICIs for treating 20 different cancer types. These therapies work by enhancing the immune system's ability to recognize and attack cancer cells. New studies highlight how therapies that target PD1 and LAG3 can work together to enhance T cell responses, particularly in the context of melanoma.

II. **CAR T-cell Therapy: Six CAR T-cell therapies** have been approved for various hematologic cancers, which involve modifying a patient's T cells to better target cancer cells.

III. **Bispecific Antibodies:** The FDA has **also approved six bispecific antibodies** that engage T cells to target and destroy cancer cells, expanding treatment options for rare cancers.

IV. **Immunogenic Cell Injury for Cancer Treatment:** Research led by the MIT team has introduced the concept of immunogenic cell injury rather than immunogenic cell death to stimulate the immune system in cancer treatment. This approach involves using injured tumor cells that are still alive to activate T cells, showing promising results in both laboratory settings and animal studies.

3- Nanotechnology and Vaccine Development

The development of **NanoSTING**, a nasal spray aimed at preventing and treating respiratory viruses, represents a breakthrough in using nanotechnology to activate the immune system against viral pathogens.

4- COVID-19 and Immune Response Studies

Research has focused on the phenomenon of "immune breakthroughs" in the context of COVID-19. Studies indicate that individuals with prior infections or vaccinations can still experience breakthrough infections due to factors like high viral load and variant strains. Understanding these immune responses is vital for improving COVID-19 prevention strategies and treatment protocols.



5- Neuroimmunology Insights:

Recent studies have explored the role of immune responses in neuroinflammation and neurodegenerative diseases. Notable findings include the impact of the IL-1β–STAT5 axis on steroid resistance in autoimmune neuroinflammation, suggesting new therapeutic targets for treating conditions like multiple sclerosis.

6- Emerging Research Directions

I. **Immunometabolism:** Investigations into the electron transport chain's role in immunometabolism are revealing how metabolic processes influence immune cell function and responses.

II. **Single-Cell Technologies:** Advances in single-cell analysis are allowing researchers to map B cell trajectories and understand immune cell interactions at unprecedented resolution, which could lead to new therapeutic strategies.

III. **Cross-Species Immune Responses:** Studies are examining immune responses across species, potentially leading to innovative treatments by leveraging insights from animal models.

IV. **Macrophage and T Cell Research**: Discoveries include a new population of macrophages that aid in lung repair after viral infections and the enhancement of natural killer cells for treating cancers like glioblastoma. These advances contribute to a better understanding of the immune system's components and their roles in disease and recovery.

7- Recent FDA Approvals in Immunotherapy:

I. **Lifileucel (Lifileucel):** Received accelerated approval on February 16, 2022, for unresectable or metastatic melanoma. This therapy is a tumor-infiltrating lymphocyte (TIL) therapy, which involves extracting immune cells from a patient's tumor, expanding them in the lab, and infusing them back to help fight the cancer.

II. **Axicabtagene Ciloleucel (Yescarta):** Approved on April 1, 2022, **for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months**. This **CAR T-cell** therapy represents a significant advancement in treating aggressive lymphomas.

III. **Pembrolizumab (Keytruda):** In March 2022, it was approved for advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), marking a vital addition to treatment options for this cancer type.

IV. **Capivasertib:** Approved in late 2023 for breast cancer, **this drug works by inhibiting the AKT protein in the PI3K signaling pathway**, which is crucial for cancer cell growth and survival.

V. **Belzutifan (Welireg):** Approved for advanced kidney cancers that **have received prior immunotherapy and a VEGF TKI, offering a new option for patients with difficult-to-treat tumors.**

VI. **Afamitresgene Autoleucel** (TECELRA): Approved on August 2, 2024, **this is a tumor-infiltrating lymphocyte (TIL) therapy for patients with unresectable or metastatic melanoma.** This marks a significant advancement in cell-based immunotherapy, leveraging the patient's own immune cells to target cancer.

VII. **Lifileucel (Amtagvi):** On February 16, 2024, the FDA granted accelerated **approval for this autologous T cell immunotherapy for adult patients with unresectable or metastatic melanoma who have previously been treated with a PD-1 blocking antibody.** This therapy utilizes T cells derived from the patient's tumor.

VIII. **Ciltacavtagene Autoleucel (cilta-cel):** Approved in April 2024, **this CAR T-cell therapy is indicated for patients with relapsed or refractory multiple myeloma**. It has shown promising results in clinical trials, providing a new option for patients who have undergone prior treatments.

IX. **Enfortumab Vedotin-ejfv (Anktiva):** This **novel interleukin-15 receptor agonist was approved for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).** The approval is based on significant clinical responses observed in trials.

B) Key Updates in Hypersensitivity Treatment

Recent advancements in the treatment of hypersensitivity reactions have focused on improving management strategies for various types of allergic responses, including anaphylaxis, food allergies, and drug hypersensitivity.

Here are the latest updates:

1- New FDA Approvals

I. **Omalizumab (Xolair):** In 2024, the FDA approved Xolair for reducing allergic reactions in patients with multiple food allergies. This is a significant development as **it is the first medication designed to mitigate allergic reactions to more than one type of food after accidental exposure**. While it does not eliminate food allergies, it helps reduce the severity of reactions, including anaphylaxis, when exposure occurs.

II. **Neffy (Epinephrine Nasal Spray): Also approved in 2024, Neffy is the first nasal spray for the emergency treatment of anaphylaxis. This needle-free option may help patients, especially children, who fear injections, thereby improving access to life-saving treatment during anaphylactic episodes.**

2- Advances in Drug Hypersensitivity Management

Recent research has highlighted the need for better management strategies for drug hypersensitivity reactions, particularly those related to biologics. **This is particularly focused on biologics like TNF-α inhibitors used in the treatment of allergic diseases. Monoclonal antibodies, such as omalizumab, dupilumab, and others, have been associated with hypersensitivity reactions, which can be immediate or delayed.**

New guidelines emphasize:

I. **Desensitization Protocols:** For patients experiencing hypersensitivity to biologics, desensitization may be a viable option to continue treatment safely. This involves gradually introducing the drug in controlled settings to build tolerance.

II. **Identification and Management: Improved diagnostic methods, including skin testing and clinical evaluation**, are essential for accurately identifying hypersensitivity reactions. This ensures appropriate management and minimizes the risk of severe reactions.

3- Innovative Therapeutic Approaches

I. **Nanoparticle Therapy:** Researchers at Northwestern University **have developed a novel therapy using decorated nanoparticles that can prevent allergic reactions.** This approach selectively targets mast cells responsible for specific allergies by carrying the relevant allergen and antibodies that inhibit mast cell activation. In preclinical studies, this method showed promise in preventing allergic responses without systemic immunosuppression, marking a significant advancement in allergy treatment.

4- Enhanced Management Strategies for Anaphylaxis

Recent reviews and studies have underscored the importance of immediate and effective management of anaphylaxis, including:

I. **Epinephrine Administration: Epinephrine remains the first-line treatment for anaphylaxis.** Guidelines emphasize the need for rapid administration and the availability of **auto-injectors or nasal sprays like Neffy** for emergency use.

II. **Education and Training: Increased awareness and training for patients and caregivers on recognizing anaphylaxis symptoms and the importance of carrying emergency epinephrine are crucial for improving outcomes.**

5- Ongoing Research and Future Directions

The field continues to evolve with ongoing research into the mechanisms of hypersensitivity and the development of targeted therapies. Future studies are expected to focus on refining desensitization protocols, exploring new biologic agents, and enhancing the safety profiles of existing treatments.

These advancements reflect a growing understanding of hypersensitivity reactions and the need for tailored approaches to manage these potentially life-threatening conditions effectiv

References

1. Massachusetts Institute of Technology (MIT). 'New cancer treatment may reawaken the immune system.'
2. ScienceDaily. 'Discovery of a new population of macrophages promoting lung repair after viral infections.'
3. MedicalXpress. 'Two new studies show how immunotherapies collaborate to boost T cell responses in melanoma.'
4. UPI. 'FDA approves nasal injection epinephrine for anaphylaxis, reaction.'
5. Frontiers. 'Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management.'
6. MDPI Biomedicines. 'Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies.'
7. American Academy of Allergy, Asthma, and Immunology (AAAAI). 'New Guidelines for Anaphylaxis and Atopic Dermatitis.'